Benzinga
21 Oct 2025, 12:16 UTC · 47w ago
Verdict
Headline leans bearish. We score NEUP −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Neuphoria Therapeutics (NEUP) trial for social anxiety failed to meet endpoints.
So whatClinical trial failure is a catastrophic event for biotech companies, evidenced by the stock's 65.3% pre-market plunge.
More negative than 99% of claims this week
PACCAR (PCAR) missed both Q3 earnings and sales consensus estimates.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 91% of claims this week
Galapagos NV (GLPG) intends to wind down its Cell Therapy Business.
More negative than 86% of claims this week
Citius Pharmaceuticals (CTXR) announced a $6 million registered direct offering.
So whatDirect offerings typically cause immediate share dilution, leading to a decrease in stock price.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
Shares plunged 65.3% after its AFFIRM-1 trial for social anxiety failed to meet endpoints.
More negative than 95% of ticker scores this week
The company reported downbeat third-quarter earnings and sales that missed analyst estimates, causing shares to fall.
More negative than 87% of ticker scores this week
Shares fell 18.2% following the announcement of a $6 million registered direct offering.
More negative than 87% of ticker scores this week
Shares declined 15.4% after the company announced plans to wind down its Cell Therapy Business.
More negative than 79% of ticker scores this week
The stock fell 9.9% in pre-market trading.
More negative than 79% of ticker scores this week
The stock fell 8.6% in pre-market trading.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
−75.5%
Price agrees with the score
$3.78 vs $15.40 close before publication (Oct 20) · not market-adjusted
NEUP chart →
